North America Human Leukocyte Antigens (HLAs) Typing Transplant Diagnostics Services Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

North America Human Leukocyte Antigens (HLAs) Typing Transplant Diagnostics Services Market Size

• The North America Human Leukocyte Antigens (HLAs) Typing Transplant Diagnostics Services Market size was valued at USD 1.64 billion in 2025 and is expected to reach USD 3.37 billion by 2033, at a CAGR of 9.45% during the forecast period
• The market growth is largely fueled by the increasing number of organ transplant procedures worldwide, rising prevalence of chronic diseases, and growing need for accurate donor-recipient matching, leading to greater adoption of advanced diagnostic solutions in healthcare settings
• Furthermore, rising demand for precise and reliable tissue typing, advancements in molecular diagnostic technologies, and increasing awareness regarding transplant compatibility are establishing Human Leukocyte Antigens (HLAs) Typing Transplant Diagnostics Services as essential components in modern transplant medicine. These converging factors are accelerating the uptake of Human Leukocyte Antigens (HLAs) Typing Transplant Diagnostics Services solutions, thereby significantly boosting the industry's growth

North America Human Leukocyte Antigens (HLAs) Typing Transplant Diagnostics Services Market Analysis

• Human Leukocyte Antigens (HLAs) typing transplant diagnostic services, enabling accurate donor-recipient matching and reducing transplant rejection risks, are increasingly vital in modern healthcare systems due to their critical role in organ and stem cell transplantation
• The escalating demand for HLA typing services is primarily fueled by the rising number of organ transplant procedures, increasing prevalence of chronic diseases, and growing adoption of advanced molecular diagnostic technologies such as PCR and next-generation sequencing
• The U.S. dominated the North America Human Leukocyte Antigens (HLAs) Typing Transplant Diagnostics Services Market with the largest revenue share of approximately 37.9% in 2025, supported by advanced healthcare infrastructure, high transplant volumes, and the strong presence of leading diagnostic service providers. The country is witnessing substantial growth in HLA typing services across transplant centers and diagnostic laboratories, driven by continuous technological advancements and increasing awareness of transplant compatibility testing
• Canada is expected to be the fastest-growing region in the North America Human Leukocyte Antigens (HLAs) Typing Transplant Diagnostics Services Market during the forecast period, registering a CAGR of approximately 8.8%, driven by rising healthcare investments, increasing awareness of organ transplantation, and expanding adoption of advanced molecular diagnostic technologies across hospitals and research institutions
• The diagnostics segment accounted for the largest market revenue share of 63.5% in 2025, driven by the critical role of HLA typing in organ transplantation and donor-recipient matching

Report Scope and North America Human Leukocyte Antigens (HLAs) Typing Transplant Diagnostics Services Market Segmentation        

North America Human Leukocyte Antigens (HLAs) Typing Transplant Diagnostics Services Market Trends

“Increasing Adoption of Advanced Molecular Typing Technologies in Transplant Diagnostics”

• A significant and accelerating trend in the global North America Human Leukocyte Antigens (HLAs) Typing Transplant Diagnostics Services Market is the growing adoption of advanced molecular typing technologies to improve transplant compatibility and patient outcomes. This trend is driven by the increasing need for precise donor-recipient matching in organ and stem cell transplantation procedures
• For instance, next-generation sequencing (NGS) and polymerase chain reaction (PCR)-based typing methods are increasingly being utilized by diagnostic laboratories and transplant centers to achieve high-resolution HLA typing, ensuring better matching accuracy and reduced risk of graft rejection
• Continuous advancements in diagnostic technologies, including automated platforms, high-throughput systems, and improved data analysis tools, are enhancing the speed, accuracy, and reliability of HLA typing services. These innovations are enabling laboratories to process larger sample volumes with greater efficiency
• The integration of advanced HLA typing techniques into routine transplant workflows is further supporting market growth. Healthcare providers are increasingly relying on precise and rapid diagnostic solutions to improve clinical decision-making and optimize transplant success rates
• This trend toward more accurate, efficient, and technologically advanced diagnostic services is reshaping transplantation practices and increasing the demand for specialized HLA typing services across hospitals, research institutes, and diagnostic laboratories
• The demand for reliable transplant diagnostics services is growing rapidly due to the rising number of organ transplants, increasing awareness about donor compatibility, and expanding global transplant programs

North America Human Leukocyte Antigens (HLAs) Typing Transplant Diagnostics Services Market Dynamics

Driver

“Rising Number of Organ Transplants and Increasing Prevalence of Chronic Diseases”

• The increasing number of organ and tissue transplant procedures worldwide is a major driver for the growth of the HLA typing transplant diagnostics services market
• Rising incidences of chronic diseases such as kidney failure, liver disorders, and hematological conditions are significantly contributing to the demand for transplant procedures
• For instance, the growing prevalence of end-stage renal disease (ESRD) has led to an increase in kidney transplant procedures, thereby driving the need for accurate HLA typing to ensure donor-recipient compatibility and improve transplant success rates
• Healthcare providers are increasingly recognizing the importance of precise HLA matching in reducing the risk of graft rejection and improving long-term transplant outcomes, which is further boosting demand for advanced diagnostic services
• In addition, the expansion of donor registries, government initiatives to promote organ donation, and improvements in healthcare infrastructure are supporting the growth of transplant programs globally
• The growing focus on personalized medicine and precision diagnostics is further encouraging the adoption of advanced HLA typing services across hospitals, transplant centers, and diagnostic laboratories

Restraint/Challenge

“High Costs and Limited Accessibility of Advanced Diagnostic Services”

• The high cost associated with advanced HLA typing technologies and transplant diagnostic services is a significant challenge, particularly in developing regions with limited healthcare resources. Sophisticated techniques such as next-generation sequencing and high-resolution molecular typing require substantial investment in equipment, reagents, and skilled personnel
• For instance, smaller diagnostic laboratories and healthcare facilities may face financial constraints in adopting advanced HLA typing platforms, limiting access to accurate and timely diagnostic services for patients requiring transplants
• In addition, limited awareness and lack of trained professionals in certain regions can hinder the effective utilization of these advanced diagnostic solutions. The complexity of testing procedures and interpretation of results further adds to operational challenges
• Variability in regulatory frameworks and reimbursement policies across different countries can also restrict market growth by delaying the adoption of new technologies and limiting patient access to these services
• Overcoming these challenges will require cost-effective diagnostic solutions, expansion of laboratory infrastructure, enhanced training programs for healthcare professionals, and increased awareness regarding the importance of HLA typing in improving transplant success rates and patient outcomes

North America Human Leukocyte Antigens (HLAs) Typing Transplant Diagnostics Services Market Scope

The market is segmented on the basis of product and services, application, end-user, distribution channel, and technology.

• By Product and Services

On the basis of product and services, the North America Human Leukocyte Antigens (HLAs) Typing Transplant Diagnostics Services Market is segmented into instruments, reagents and consumables, and software and services. The reagents and consumables segment dominated the largest market revenue share of 46.8% in 2025, driven by their recurring usage in HLA typing procedures for transplantation diagnostics. These products are essential for PCR and sequencing-based assays, ensuring continuous demand across laboratories and hospitals. Increasing organ transplant procedures globally are significantly boosting consumption. Laboratories rely heavily on high-quality reagents for accurate and reproducible results. Technological advancements in assay kits are enhancing efficiency and turnaround time. Growing awareness regarding organ donation and compatibility testing further supports demand. Favorable reimbursement policies in developed regions contribute to adoption. Continuous product innovations and expansion of testing facilities are reinforcing segment dominance.

The software and services segment is expected to witness the fastest CAGR of 11.6% from 2026 to 2033, fueled by increasing demand for advanced data analysis and interpretation tools in HLA typing. Rising adoption of bioinformatics solutions for managing complex genetic data is accelerating growth. Laboratories and transplant centers are integrating software platforms for improved workflow efficiency. Cloud-based solutions and automation technologies are enhancing scalability and accessibility. Increasing reliance on outsourcing diagnostic services also contributes to growth. Emerging markets are adopting advanced service models to improve healthcare delivery. Continuous upgrades in analytical tools and database systems support expansion. Growing focus on precision medicine further drives demand.

• By Application

On the basis of application, the North America Human Leukocyte Antigens (HLAs) Typing Transplant Diagnostics Services Market is segmented into diagnostics and research. The diagnostics segment accounted for the largest market revenue share of 63.5% in 2025, driven by the critical role of HLA typing in organ transplantation and donor-recipient matching. Hospitals and transplant centers rely heavily on diagnostic testing to minimize rejection risks. Increasing number of kidney, liver, and bone marrow transplants globally is supporting demand. Advanced molecular diagnostic techniques improve accuracy and reliability. Government initiatives promoting organ donation are contributing to growth. High adoption in developed healthcare systems further strengthens dominance. Continuous improvements in turnaround time and testing efficiency enhance usability. Rising awareness among patients and healthcare providers boosts adoption.

The research segment is expected to witness the fastest CAGR of 10.9% from 2026 to 2033, driven by increasing studies in immunogenetics and transplant biology. Academic and research institutes are focusing on understanding genetic compatibility and immune responses. Rising funding for genomics research is supporting growth. Collaboration between research organizations and biotechnology companies accelerates innovation. Expansion of clinical trials and personalized medicine initiatives contributes to demand. Advanced sequencing technologies are enabling deeper insights into HLA diversity. Growing interest in disease association studies further boosts adoption. Emerging markets are increasingly investing in research infrastructure.

• By End-user

On the basis of end-user, the North America Human Leukocyte Antigens (HLAs) Typing Transplant Diagnostics Services Market is segmented into hospitals and academic and research institutes. The hospitals segment dominated the largest market revenue share of 58.2% in 2025, driven by the high volume of transplant procedures and diagnostic testing conducted in hospital settings. Hospitals are primary centers for organ transplantation and donor matching. Availability of advanced diagnostic infrastructure supports adoption. Skilled professionals and specialized laboratories enhance efficiency. Increasing patient admissions for transplant procedures drive demand. Government funding and reimbursement policies further support growth. Integration of advanced technologies improves testing accuracy. Hospitals remain the preferred choice for critical diagnostic services.

The academic and research institutes segment is expected to witness the fastest CAGR of 11.2% from 2026 to 2033, fueled by increasing focus on immunogenetics and transplant research. Universities and research centers are investing in advanced HLA typing technologies. Growing collaborations with healthcare providers and biotech firms support expansion. Rising funding for genomics and precision medicine research accelerates adoption. Development of innovative diagnostic techniques enhances future potential. Expansion of research infrastructure in emerging markets contributes to growth. Increasing number of clinical studies further drives demand.

• By Distribution Channel

On the basis of distribution channel, the North America Human Leukocyte Antigens (HLAs) Typing Transplant Diagnostics Services Market is segmented into direct tender, hospital pharmacies, retail pharmacies, online pharmacies, and others. The direct tender segment dominated the largest market revenue share of 41.7% in 2025, driven by bulk procurement by hospitals, laboratories, and government organizations. Direct purchasing ensures cost efficiency and consistent supply of diagnostic products. Large healthcare institutions prefer tender-based procurement for high-volume usage. Strong relationships between manufacturers and healthcare providers support growth. Government initiatives and public healthcare programs further boost demand. Streamlined supply chain management enhances efficiency. Increasing number of diagnostic centers contributes to segment expansion.

The online pharmacies segment is expected to witness the fastest CAGR of 12.4% from 2026 to 2033, driven by the growing adoption of digital platforms for procurement of diagnostic products. Convenience, accessibility, and competitive pricing are key factors supporting growth. Increasing digitalization in healthcare supply chains enhances adoption. Small laboratories and clinics prefer online channels for quick procurement. Expansion of e-commerce platforms globally contributes to demand. Improved logistics and delivery networks support market growth. Rising internet penetration in emerging markets accelerates adoption.

• By Technology

On the basis of technology, the North America Human Leukocyte Antigens (HLAs) Typing Transplant Diagnostics Services Market is segmented into polymerase chain reaction and next-generation sequencing. The polymerase chain reaction (PCR) segment dominated the largest market revenue share of 55.6% in 2025, driven by its widespread use, cost-effectiveness, and high accuracy in HLA typing. PCR-based methods are well-established and widely adopted in clinical diagnostics. Laboratories prefer PCR for its quick turnaround time and reliability. Increasing transplant procedures globally support demand. Continuous improvements in PCR techniques enhance sensitivity and specificity. Strong presence in both developed and emerging markets reinforces dominance.

The next-generation sequencing (NGS) segment is expected to witness the fastest CAGR of 13.1% from 2026 to 2033, fueled by its ability to provide high-resolution and comprehensive genetic analysis. NGS enables precise allele-level typing, improving transplant outcomes. Increasing adoption of precision medicine drives demand. Technological advancements are reducing sequencing costs and improving accessibility. Research institutions and advanced hospitals are rapidly integrating NGS platforms. Growing focus on personalized healthcare further supports growth. Expansion in emerging markets contributes to rapid adoption.

North America Human Leukocyte Antigens (HLAs) Typing Transplant Diagnostics Services Market Regional Analysis

• North America dominated the North America Human Leukocyte Antigens (HLAs) Typing Transplant Diagnostics Services Market with the largest revenue share of approximately 39.2% in 2025, supported by advanced healthcare infrastructure, high transplant rates, and the strong presence of leading diagnostic service providers
• The region benefits from a well-established network of transplant centers, diagnostic laboratories, and research institutions that extensively utilize advanced HLA typing technologies to ensure accurate donor-recipient matching and improved transplant outcomes
• This widespread adoption is further supported by high healthcare expenditure, favorable reimbursement policies, and continuous technological advancements in molecular diagnostics, establishing HLA typing services as a critical component in transplant procedures and precision medicine

U.S. North America Human Leukocyte Antigens (HLAs) Typing Transplant Diagnostics Services Market Insight

The U.S. North America Human Leukocyte Antigens (HLAs) Typing Transplant Diagnostics Services Market dominated the North America Human Leukocyte Antigens (HLAs) Typing Transplant Diagnostics Services Market with the largest revenue share of approximately 37.9% in 2025, supported by advanced healthcare infrastructure, high transplant volumes, and the strong presence of leading diagnostic service providers. The country is witnessing substantial growth in HLA typing services across transplant centers and diagnostic laboratories, driven by continuous technological advancements such as next-generation sequencing (NGS) and high-resolution molecular typing methods. Additionally, increasing awareness of transplant compatibility testing, along with the expansion of donor registries and supportive government initiatives promoting organ donation, is further propelling market growth.

Canada North America Human Leukocyte Antigens (HLAs) Typing Transplant Diagnostics Services Market Insight

The Canada North America Human Leukocyte Antigens (HLAs) Typing Transplant Diagnostics Services Market is expected to be the fastest-growing during the forecast period, registering a CAGR of approximately 8.8%. This growth is driven by rising healthcare investments, increasing awareness of organ transplantation, and expanding adoption of advanced molecular diagnostic technologies across hospitals and research institutions. Furthermore, improvements in healthcare infrastructure, growing focus on precision medicine, and increasing support from public health initiatives are encouraging the adoption of HLA typing services, contributing to sustained market growth in the country.

North America Human Leukocyte Antigens (HLAs) Typing Transplant Diagnostics Services Market Share

The Human Leukocyte Antigens (HLAs) Typing Transplant Diagnostics Services industry is primarily led by well-established companies, including:

• Thermo Fisher Scientific Inc. (U.S.)
• QIAGEN N.V. (Netherlands)
• Bio-Rad Laboratories, Inc. (U.S.)
• Illumina, Inc.((U.S.)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Abbott (U.S.)
• Agilent Technologies, Inc. (U.S.)
• Luminex Corporation (U.S.)
• GenDx (Netherlands)
• Omixon Biocomputing Ltd. (Hungary)
• CareDx, Inc. (U.S.)
• Immucor, Inc. (U.S.)
• Biofortuna Ltd. (U.K.)
• TBG Diagnostics Limited (Australia)
• HistoGenetics LLC (U.S.)
• PIRCHE AG (Germany)
• Fujirebio (Japan)
• Randox Laboratories Ltd. (U.K.)
• Natera, Inc. (U.S.)
• Eurofins Scientific (Luxembourg)

Latest Developments in North America Human Leukocyte Antigens (HLAs) Typing Transplant Diagnostics Services Market

• In October 2023, the global HLA typing for transplant diagnostics market was highlighted in an industry report estimating its value at USD 0.8 billion in 2023 with projected growth to USD 1.1 billion by 2028, driven by increasing adoption of molecular diagnostic technologies and the rising need for precise donor-recipient matching in organ transplantation. This development reflects growing demand for advanced HLA typing services globally
• In August 2024, Thermo Fisher Scientific Inc. received U.S. FDA 510(k) clearance for its SeCore CDx HLA A Sequencing System, a companion diagnostic designed to identify specific HLA-A alleles in patients eligible for targeted cell therapies such as afamitresgene autoleucel. The system uses sequence-based typing methods to improve precision in transplant compatibility and immunotherapy selection, marking a key advancement in HLA diagnostic technologies
• In June 2024, healthcare authorities in British Columbia, Canada, introduced an innovative HLA-based donor-recipient matching approach aimed at reducing organ rejection and minimizing reliance on long-term immunosuppressive drugs. This initiative demonstrated the growing integration of advanced HLA typing methods into real-world transplant programs to improve patient outcomes
• In May 2024, Christian Medical College (CMC), Vellore, announced expanded financial support programs covering HLA typing and transplant diagnostics services for economically disadvantaged patients undergoing hematopoietic stem cell transplantation. This development improved accessibility to essential transplant diagnostic services, particularly in emerging markets

SKU-19107